Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis

Transfusion

Volumn 50, Issue 4, 2010, Pages 801-807

  Genzen, Jonathan R ^a,b,c,d   Fareed, Jawed ^a,b,c,d   Hoppensteadt, Debra ^a,b,c,d   Kurup, Viji ^a,b,c,d   Barash, Paul ^a,b,c,d   Coady, Michael ^a,b,c,d   Wu, Yan Yun ^a,b,c,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c BROWN UNIVERSITY   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; ECARIN; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN INHIBITOR;

AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; BLOOD SAMPLING; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CASE REPORT; CRITICALLY ILL PATIENT; CRYOPRECIPITATE; DRUG BLOOD LEVEL; ERYTHROCYTE TRANSFUSION; HEART TRANSPLANTATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTRAOPERATIVE PERIOD; MALE; POSTOPERATIVE HEMORRHAGE; SIDE EFFECT; SURGICAL PATIENT; THROMBOCYTE TRANSFUSION; THROMBOSIS;

AGED; BLOOD COAGULATION DISORDERS; CARDIOPULMONARY BYPASS; CHILD; HEART TRANSPLANTATION; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 77950214512     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02531.x     Document Type: Article

References (32)

1. Furukawa K, Ohteki H, Hirahara K, Narita Y, Koga S. The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations. J Thorac Cardiovasc Surg 2001 122 : 1255 6.
2. Ohno H, Higashidate M, Yokosuka T. Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary bypass surgery. Heart Vessels 2003 18 : 40 2.
3. Edwards JT, Hamby JK, Worrall NK. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 2003 75 : 1622 4.
4. Dyke PC 2nd., Russo P, Mureebe L, Russo J, Tobias JD. Argatroban for anticoagulation during cardiopulmonary bypass in an infant. Paediatr Anaesth 2005 15 : 328 33.
5. Gasparovic H, Nathan NS, Fitzgerald D, Aranki SF. Severe argatroban-induced coagulopathy in a patient with a history of heparin-induced thrombocytopenia. Ann Thorac Surg 2004 78 : e89 91.
6. Malherbe S, Tsui BC, Stobart K, Koller J. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology 2004 100 : 443 5.
7. Cannon M, Butterworth J, Riley R, Hyland J. Failure of argatroban anticoagulation during off-pump coronary artery bypass. Ann Thorac Surg 2004 77 : 711 33.
8. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000 20 : 318 29.
9. GlaxoSmithKline. Prescribing information: argatroban. Research Triangle Park (NC) : GlaxoSmithKline May 2008.
10. Kurup V, Transue S, Wu Y, Rinder HM, Barash P, Dewar M. Cardiac surgery in a patient with heparin-induced thrombocytopenia - cautions with use of the direct thrombin inhibitor, argatroban. Conn Med 2006 70 : 245 50.
11. Nowak G, Bucha E. A new method for the therapeutical monitoring of hirudin. XIVth Congress of the International Society on Thrombosis and Haemostasis, Vol. 69. New York : Thrombosis and Haemostasis 1993 1306.
12. Ahmad S, Ahsan A, Iqbal O, Walenga J, Lewis B, Fareed J. Studies on biochemical and pharmacological properties of argatroban in man: potential clinical implications. In : Savage L, Thibeaul C, editors. Anticoagulant, antithrombotic, and thrombolytic therapeutics II, Vol. 1924. Sothborough (MA) : IBC Library Series 1998 233.
13. Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006 129 : 1167 75.
14. Smith AI, Stroud R, Damiani P, Vaynblat M. Use of argatroban for anticoagulation during cardiopulmonary bypass in a patient with heparin allergy. Eur J Cardiothorac Surg 2008 34 : 1113 4.
15. Swan SK, St Peter JV, Lambrecht LJ, Hursting MJ. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000 20 : 756 70.
16. Ahmad S, Ahsan A, Iqbal O, Hoppensteadt DA, Lewis BE, Walenga JM, Fareed J. Pharmacokinetics and pharmacodynamics of argatroban as studied by HPLC and functional methods: implications in the monitoring and dosage-optimizations in cardiovascular patients. Clin Appl Thromb Hemost 1998 4 : 243 9.
17. Walenga JM, Fasanella AR, Iqbal O, Hoppensteadt DA, Ahmad S, Wallis DE, Bakhos M. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999 25 Suppl 1 : 61 6.
18. Iqbal O, Ahmad S, Lewis BE, Walenga JM, Rangel RN, Fareed J. Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology. Clin Appl Thromb Hemost 2002 8 : 214 24.
19. de Denus S, Spinler SA. Decreased argatroban clearance unaffected by hemodialysis in anasarca. Ann Pharmacother 2003 37 : 1237 40.
20. Hoffman WD, Czyz Y, McCollum DA, Hursting MJ. Reduced argatroban doses after coronary artery bypass graft surgery. Ann Pharmacother 2008 42 : 309 16.
21. Begelman SM, Baghdasarian SB, Singh IM, Militello MA, Hursting MJ, Bartholomew JR. Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure. J Intensive Care Med 2008 23 : 313 20.
22. Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 2003 37 : 652 4.
23. Beiderlinden M, Treschan TA, Gorlinger K, Peters J. Argatroban anticoagulation in critically ill patients. Ann Pharmacother 2007 41 : 749 54.
24. Dager WE. Considerations for drug dosing post coronary artery bypass graft surgery. Ann Pharmacother 2008 42 : 421 4.
25. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 133 : 340S 80S.
26. Ahmad S, Ahsan A, George M, Iqbal O, Jeske WP, McKenna R, Lewis BE, Walenga JM, Fareed J. Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications. Clin Appl Thromb Hemost 1999 5 : 252 8.
27. Nuttall GA, Oliver WC Jr., Santrach PJ, McBane RD, Erpelding DB, Marver CL, Zehr KJ. Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesth Analg 2003 96 : 344 50.
28. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003 121 : 535 55.
29. Potzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000 343 : 515.
30. Lubenow N, Selleng S, Wollert HG, Eichler P, Mullejans B, Greinacher A. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann Thorac Surg 2003 75 : 577 9.
31. Koster A, Buz S, Hetzer R, Kuppe H, Breddin K, Harder S. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial. J Thorac Cardiovasc Surg 2006 132 : 699 700.
32. Selleng S, Haneya A, Hirt S, Selleng K, Schmid C, Greinacher A. Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood 2008 112 : 4024 7.